Coya Therapeutics (NASDAQ:COYA) Coverage Initiated at Lake Street Capital

Research analysts at Lake Street Capital began coverage on shares of Coya Therapeutics (NASDAQ:COYA - Get Free Report) in a research report issued on Wednesday, Marketbeat Ratings reports. The firm set a "buy" rating and a $16.00 price target on the stock. Lake Street Capital's price objective would indicate a potential upside of 161.01% from the stock's previous close.

Several other equities analysts have also commented on COYA. HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, June 9th. Chardan Capital restated a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Tuesday, July 1st. Wall Street Zen lowered shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, D. Boral Capital restated a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

Coya Therapeutics Stock Down 3.0%

NASDAQ:COYA traded down $0.19 on Wednesday, hitting $6.13. The stock had a trading volume of 74,445 shares, compared to its average volume of 73,047. The stock has a market cap of $102.55 million, a price-to-earnings ratio of -5.73 and a beta of 0.26. The company has a fifty day moving average price of $5.81 and a two-hundred day moving average price of $6.03. Coya Therapeutics has a 1-year low of $4.65 and a 1-year high of $10.24.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, meeting the consensus estimate of ($0.44). The firm had revenue of $257.88 million during the quarter, compared to analyst estimates of $2.63 million. As a group, analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its holdings in Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after buying an additional 4,777 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Coya Therapeutics in the 4th quarter valued at approximately $59,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Coya Therapeutics in the 1st quarter valued at approximately $65,000. Jane Street Group LLC purchased a new stake in shares of Coya Therapeutics in the 4th quarter valued at approximately $74,000. Finally, Northern Trust Corp increased its position in shares of Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after purchasing an additional 3,099 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.